• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AbbVie (ABBV) Could Be 4% Undervalued After Phase 3 Trial Wins

    Simply Wall St·09/17/2026 13:21:32
    Listen to the news

    AbbVie (ABBV) is back in focus after fresh Phase 3 wins for etentamig in multiple myeloma and atogepant in menstrual migraine, reshaping how investors view its oncology and neuroscience pipeline.

    Recent gains show how quickly sentiment has shifted around AbbVie. The stock has delivered a 90 day share price return of 21.26% and a year to date share price return of 14.48%, while total shareholder return over five years sits at about 196.39%. This points to long term compounding as new data, acquisitions and a reaffirmed dividend track record reshape expectations around its pipeline strength and cash generation potential.

    Scan how AbbVie’s surge compares with other healthcare compounders by checking our hand picked 11 resilient stocks with low risk scores that sit on resilient balance sheets and steady fundamentals.

    AbbVie now trades near record highs after this rally. However, the discounted cash flow work still points to meaningful upside. How much of the story is already in the price, and how much remains uncounted in the current valuation?

    Most Popular Narrative: 4% Undervalued

    AbbVie closed at $262.51, while the most followed narrative pegs fair value near $273.39. This frames the rally as still leaving some room based on refreshed cash flow and earnings assumptions that use a 7.64% discount rate.

    Advancements and strategic investments in neuroscience, including strong uptake of Vraylar, QULIPTA, Ubrelvy, and the emerging Parkinson's portfolio (e.g., VYALEV), align with growing demand for therapies addressing chronic neurological diseases in an aging population, supporting both revenue and long-term earnings stability.

    See why 312 investors see AbbVie as 4% undervalued.

    Result: Fair Value of $273.39 (UNDERVALUED)

    Still, AbbVie’s story can change quickly if key drugs lose exclusivity faster than expected, or if new acquisitions underperform and weigh on profitability.

    Find out about the key risks to this AbbVie narrative.

    Another View on AbbVie’s Valuation

    There is a very different message coming from AbbVie’s current P/E. The stock trades on about 74x earnings, while the US Biotechs group sits near 17.1x and a fair ratio for AbbVie is estimated at 43.3x. That gap points to clear valuation risk if expectations reset.

    For a closer look at what this premium implies in practice, including how it stacks up against peers and the fair ratio our models flag, See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:ABBV P/E Ratio as at Sep 2026
    NYSE:ABBV P/E Ratio as at Sep 2026

    Next Steps

    Feeling torn between AbbVie’s recent momentum and the valuation warning signs in the multiples? Use the full breakdown of 3 key rewards and 4 important warning signs to pressure test your own view before the story shifts again.

    Looking for more investment ideas beyond AbbVie?

    If AbbVie has you rethinking your watchlist, now is the moment to widen the net and line up your next set of potential opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.